MedinCell S.A. (EPA:MEDCL)
France · Delayed Price · Currency is EUR 24.82
-0.36 (-1.43%)
Dec 22, 2025, 4:36 PM CET
MedinCell Income Statement
Financials in millions EUR. Fiscal year is April - March.
Millions EUR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 28.41 | 25.42 | 9.03 | 9.89 | 4.09 | 8.19 | Upgrade |
Other Revenue | 4.03 | 2.31 | 2.91 | 3.77 | 4.25 | - | Upgrade |
| 32.44 | 27.73 | 11.95 | 13.66 | 8.34 | 8.19 | Upgrade | |
Revenue Growth (YoY) | 145.75% | 132.12% | -12.52% | 63.77% | 1.86% | 36.43% | Upgrade |
Gross Profit | 32.44 | 27.73 | 11.95 | 13.66 | 8.34 | 8.19 | Upgrade |
Selling, General & Admin | 14.9 | 14.18 | 11.79 | 9.72 | 8.49 | 7.44 | Upgrade |
Research & Development | 27.32 | 24.31 | 21.05 | 27.92 | 23.58 | 19.54 | Upgrade |
Other Operating Expenses | - | - | 0.04 | 0.04 | 0.08 | 0.13 | Upgrade |
Operating Expenses | 42.22 | 38.49 | 32.89 | 37.68 | 32.15 | 27.11 | Upgrade |
Operating Income | -9.78 | -10.76 | -20.94 | -24.03 | -23.81 | -18.93 | Upgrade |
Interest Expense | -5.31 | -5.09 | -4.62 | -3.93 | -1.84 | -3.58 | Upgrade |
Interest & Investment Income | 1.46 | 1.4 | 0.55 | 0.04 | 0.05 | 0.04 | Upgrade |
Currency Exchange Gain (Loss) | -0.27 | -0.23 | 0.14 | 1.17 | 0.83 | -0.23 | Upgrade |
Other Non Operating Income (Expenses) | -5.87 | -3.52 | -0.04 | -5.21 | -0.02 | 0.36 | Upgrade |
EBT Excluding Unusual Items | -19.76 | -18.2 | -24.91 | -31.95 | -24.8 | -22.34 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | -0.04 | - | - | Upgrade |
Other Unusual Items | -0.15 | -0.08 | -0.04 | -0.02 | -0 | 3.35 | Upgrade |
Pretax Income | -19.91 | -18.28 | -24.95 | -32.01 | -24.81 | -18.99 | Upgrade |
Income Tax Expense | 0.04 | 0.16 | 0.09 | - | - | - | Upgrade |
Earnings From Continuing Operations | -19.95 | -18.44 | -25.04 | -32.01 | -24.81 | -18.99 | Upgrade |
Net Income | -19.95 | -18.44 | -25.04 | -32.01 | -24.81 | -18.99 | Upgrade |
Net Income to Common | -19.95 | -18.44 | -25.04 | -32.01 | -24.81 | -18.99 | Upgrade |
Shares Outstanding (Basic) | 32 | 30 | 28 | 25 | 25 | 22 | Upgrade |
Shares Outstanding (Diluted) | 32 | 30 | 28 | 25 | 25 | 22 | Upgrade |
Shares Change (YoY) | 8.92% | 4.28% | 12.83% | 1.39% | 12.79% | 9.52% | Upgrade |
EPS (Basic) | -0.63 | -0.62 | -0.88 | -1.27 | -1.00 | -0.86 | Upgrade |
EPS (Diluted) | -0.63 | -0.62 | -0.88 | -1.27 | -1.00 | -0.86 | Upgrade |
Free Cash Flow | -17.68 | 18.72 | -12.25 | -21.58 | -22.99 | -12.78 | Upgrade |
Free Cash Flow Per Share | -0.56 | 0.63 | -0.43 | -0.86 | -0.93 | -0.58 | Upgrade |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade |
Operating Margin | -30.14% | -38.81% | -175.30% | -175.94% | -285.58% | -231.21% | Upgrade |
Profit Margin | -61.49% | -66.50% | -209.61% | -234.42% | -297.50% | -231.93% | Upgrade |
Free Cash Flow Margin | -54.50% | 67.51% | -102.52% | -158.04% | -275.67% | -156.11% | Upgrade |
EBITDA | -9.57 | -10.07 | -20.05 | -23.05 | -22.95 | -18.12 | Upgrade |
EBITDA Margin | -29.50% | -36.32% | -167.83% | -168.81% | -275.23% | -221.40% | Upgrade |
D&A For EBITDA | 0.21 | 0.69 | 0.89 | 0.97 | 0.86 | 0.8 | Upgrade |
EBIT | -9.78 | -10.76 | -20.94 | -24.03 | -23.81 | -18.93 | Upgrade |
EBIT Margin | -30.14% | -38.81% | -175.30% | -175.94% | -285.58% | -231.21% | Upgrade |
Revenue as Reported | 32.44 | 27.73 | 11.95 | 13.66 | 8.34 | 11.78 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.